Anu Anna George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anu Anna George has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Kumar Mishra
Department of Cardiology, Concord Hospital, Concord, NH 03301, USA
5 shared publications - Amos Lal
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
4 shared publications - Kamal Kant Sahu
Department of Internal Medicine, Huntsman Cancer Institute, University of Utah
4 shared publications - Jennifer Sargent
Department of Internal Medicine, St Vincent Hospital, Worcester, United States
2 shared publications Ajay Kumar Mishra
Department of General Medicine, Christian Medical College, Vellore, Tamil Nadu, India
1 shared publicationAnil Jha
Fellow in Cardiovascular Medicine, Saint Vincent Hospital, Worcester, MA, USA
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. 24 (3) , e166723
Discordantly Low HbA1c in Patients Receiving Dapsone: Prevalence and Associations with Hemolysis and Methemoglobinemia
Background: Glycosylated hemoglobin (HbA1c) is widely used for the diagnosis and long-term monitoring of diabetes mellitus (DM). However, its accuracy may be compromised by conditions and medications that alter erythrocyte lifespan or hemoglobin structure. Dapsone, commonly used in the treatment of Hansen’s disease, has been reported to cause spuriously low HbA1c values, but systematic data on its prevalence and underlying mechanisms remain limited. Objectives: The objectives of this study were to (1) determine the prevalence of discordantly low HbA1c levels in patients receiving dapsone therapy, including individuals with and without DM; (2) explore associations between discordant HbA1c and markers of hemolysis and methemoglobinemia; and (3) compare measured HbA1c values obtained by high-performance liquid chromatography (HPLC) with expected HbA1c values derived from fructosamine using the glycosyl gap. Methods: This retrospective cross-sectional study included 30 patients receiving oral dapsone for Hansen’s disease and 10 healthy controls. HbA1c was measured using ion-exchange HPLC and compared with expected HbA1c values calculated from serum fructosamine. Parameters related to hemolysis and methemoglobinemia were assessed. Discordant HbA1c was defined by a negative glycosyl gap. Subgroup analyses were exploratory. Results: Among patients receiving dapsone, 16 had DM and 14 were normoglycemic. Discordantly low HbA1c was observed in 27 of 30 patients (90%), including 15 of 16 patients with DM and 12 of 14 without diabetes. Markers of hemolysis and methemoglobinemia showed trends consistent with biological plausibility but did not demonstrate statistically significant differences sufficient to establish causality. Conclusions: A high prevalence of discordantly low HbA1c was observed among patients receiving dapsone therapy, highlighting an important clinical pitfall in the interpretation of HbA1c. While hemolysis and methemoglobinemia remain biologically plausible contributors, these findings should be considered hypothesis-generating. Clinicians should exercise caution when interpreting HbA1c in patients treated with dapsone and consider alternative glycemic markers such as fructosamine.
- 27 April 2026
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. 24 (3) , e166723
Open AccessDiscordantly Low HbA1c in Patients Receiving Dapsone: Prevalence and Associations with Hemolysis and Methemoglobinemia
Background: Glycosylated hemoglobin (HbA1c) is widely used for the diagnosis and long-term monitoring of diabetes mellitus (DM). However, its accuracy may be compromised by conditions and medications that alter erythrocyte lifespan or hemoglobin structure. Dapsone, commonly used in the treatment of Hansen’s disease, has been reported to cause spuriously low HbA1c values, but systematic data on its prevalence and underlying mechanisms remain limited. Objectives: The objectives of this study were to (1) determine the prevalence of discordantly low HbA1c levels in patients receiving dapsone therapy, including individuals with and without DM; (2) explore associations between discordant HbA1c and markers of hemolysis and methemoglobinemia; and (3) compare measured HbA1c values obtained by high-performance liquid chromatography (HPLC) with expected HbA1c values derived from fructosamine using the glycosyl gap. Methods: This retrospective cross-sectional study included 30 patients receiving oral dapsone for Hansen’s disease and 10 healthy controls. HbA1c was measured using ion-exchange HPLC and compared with expected HbA1c values calculated from serum fructosamine. Parameters related to hemolysis and methemoglobinemia were assessed. Discordant HbA1c was defined by a negative glycosyl gap. Subgroup analyses were exploratory. Results: Among patients receiving dapsone, 16 had DM and 14 were normoglycemic. Discordantly low HbA1c was observed in 27 of 30 patients (90%), including 15 of 16 patients with DM and 12 of 14 without diabetes. Markers of hemolysis and methemoglobinemia showed trends consistent with biological plausibility but did not demonstrate statistically significant differences sufficient to establish causality. Conclusions: A high prevalence of discordantly low HbA1c was observed among patients receiving dapsone therapy, highlighting an important clinical pitfall in the interpretation of HbA1c. While hemolysis and methemoglobinemia remain biologically plausible contributors, these findings should be considered hypothesis-generating. Clinicians should exercise caution when interpreting HbA1c in patients treated with dapsone and consider alternative glycemic markers such as fructosamine.
- Open Access
- 7 March 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (2) , 14-20
The Effect of Atrial Fibrillation on Mortality Outcomes in Patients Admitted with Diabetic Ketoacidosis.
This study aims to identify the effect of atrial fibrillation on mortality in patients admitted with DKA. We used the National Inpatient Sample Database for the year 2018 and 2019 to identify patients hospitalized with DKA. Association of atrial fibrillation was confirmed using the International Classification of Disease, Tenth Edition (ICD 10 CM). We performed a retrospective analysis on this database using STATA (Stata Corp, College Station, TX). The primary outcome was mortality in DKA. Length of stay (LOS) and total hospitalization charge were the secondary outcomes. There was a total of 447,570 DKA patients out of which 12,770 had associated atrial fibrillation in the year 2018-2019. The mean age of patients with DKA and AFIB was 62 years. Approximately 46% of patients were female in DKA with AFIB group. The multivariate logistic analysis showed increased mortality in patients with DKA and AFIB (OR=1.4, p=0.048). Predictors of increased mortality were older age and teaching status of hospitals in metropolitan areas (OR=1.0, p
- 7 March 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (2) , 14-20
Open AccessThe Effect of Atrial Fibrillation on Mortality Outcomes in Patients Admitted with Diabetic Ketoacidosis.
This study aims to identify the effect of atrial fibrillation on mortality in patients admitted with DKA. We used the National Inpatient Sample Database for the year 2018 and 2019 to identify patients hospitalized with DKA. Association of atrial fibrillation was confirmed using the International Classification of Disease, Tenth Edition (ICD 10 CM). We performed a retrospective analysis on this database using STATA (Stata Corp, College Station, TX). The primary outcome was mortality in DKA. Length of stay (LOS) and total hospitalization charge were the secondary outcomes. There was a total of 447,570 DKA patients out of which 12,770 had associated atrial fibrillation in the year 2018-2019. The mean age of patients with DKA and AFIB was 62 years. Approximately 46% of patients were female in DKA with AFIB group. The multivariate logistic analysis showed increased mortality in patients with DKA and AFIB (OR=1.4, p=0.048). Predictors of increased mortality were older age and teaching status of hospitals in metropolitan areas (OR=1.0, p
- Open Access
- 10 November 2020
- Vol. 92 (1) , e2021025
Review of clinical profile, risk factors, and outcomein patients with Tuberculosis and COVID -19
Coronavirus disease (COVID 19) has involved millions of people all over the world. Tuberculosis (TB) continues to affect millions of people every year with high mortality. There is limited literature on the occurrence of COVID 19 in patients with TB. We reviewed the available data on various clinical details, management, and outcome among patients with COVID-19 and TB. 8 studies reported a total of 80 patients with this coinfection. These patients were reported from 9 different countries, with Italy reporting the largest number of cases. Migrant, males constituted a major proportion of cases. Most reported patients were symptomatic. Fever, dry cough, and dyspnea were the most commonly reported symptoms. Bilateral ground glass opacities were more common in COVID 19 infection and cavitary lesions were more common in patients with TB. Most reported TB patients had been found to have mycobacterium tuberculosis from sputum culture in the background of pulmonary TB. Most patients of TB were treated with multidrug regimen antitubercular therapy. In all 8 studies, COVID 19 was treated as per the local protocol. Mortality was reported in more than 10% of patients. Mortality was higher in elderly patients (> 70 years) and amongst patient with multiple medical comorbidities. (www.actabiomedica.it)
- 10 November 2020
- Vol. 92 (1) , e2021025
Open AccessReview of clinical profile, risk factors, and outcomein patients with Tuberculosis and COVID -19
Coronavirus disease (COVID 19) has involved millions of people all over the world. Tuberculosis (TB) continues to affect millions of people every year with high mortality. There is limited literature on the occurrence of COVID 19 in patients with TB. We reviewed the available data on various clinical details, management, and outcome among patients with COVID-19 and TB. 8 studies reported a total of 80 patients with this coinfection. These patients were reported from 9 different countries, with Italy reporting the largest number of cases. Migrant, males constituted a major proportion of cases. Most reported patients were symptomatic. Fever, dry cough, and dyspnea were the most commonly reported symptoms. Bilateral ground glass opacities were more common in COVID 19 infection and cavitary lesions were more common in patients with TB. Most reported TB patients had been found to have mycobacterium tuberculosis from sputum culture in the background of pulmonary TB. Most patients of TB were treated with multidrug regimen antitubercular therapy. In all 8 studies, COVID 19 was treated as per the local protocol. Mortality was reported in more than 10% of patients. Mortality was higher in elderly patients (> 70 years) and amongst patient with multiple medical comorbidities. (www.actabiomedica.it)
- Open Access
- 10 November 2020
- Vol. 91 (4) , e2020155
An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19).
Coronavirus 19 disease (COVID-19) continues to be a pandemic with global implications. Respiratory system involvement is the most common manifestation in symptomatic patients. In this literature review, we describe the diagnosis, management, and implications of pulmonary hypertension (PH) among patients with COVID-19. We defined pulmonary hypertension as increasing mean pulmonary artery pressure (mPAP) of ≥ 25 mm Hg at rest. In our literature search, we identified 4 articles with details on pulmonary hypertension. Among these, two reported various echocardiographic details for diagnosing pulmonary hypertension. In 1 study evidence of pulmonary hypertension was noted in 13.4% of patients. Patients with severe COVID-19 were reported to have a higher proportion of pulmonary hypertension as compared to mild COVID-19 disease [22% vs 2%]. Elevated pulmonary artery systolic pressure was significant in predicting mortality. COVID-19 patients with chronic obstructive pulmonary disease, congestive heart failure, myocardial injury, pulmonary embolism, and prior pulmonary hypertension were at a higher risk of worsening pulmonary hypertension. Multiple mechanisms for developing pulmonary hypertension that have been postulated are i) concomitant worsening myocardial injury, ii) cytokine storm, endothelial injury, hypercoagulability attributing to development of venous thromboembolism, iii) and the presence of thrombotic microangiopathy. Among patients with severe COVID-19 disease and pulmonary hypertension, complications including acute respiratory distress syndrome, acute myocardial injury, the requirement of intensive care unit admission, the requirement of mechanical ventilation, and mortality are higher.
- 10 November 2020
- Vol. 91 (4) , e2020155
Open AccessAn Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19).
Coronavirus 19 disease (COVID-19) continues to be a pandemic with global implications. Respiratory system involvement is the most common manifestation in symptomatic patients. In this literature review, we describe the diagnosis, management, and implications of pulmonary hypertension (PH) among patients with COVID-19. We defined pulmonary hypertension as increasing mean pulmonary artery pressure (mPAP) of ≥ 25 mm Hg at rest. In our literature search, we identified 4 articles with details on pulmonary hypertension. Among these, two reported various echocardiographic details for diagnosing pulmonary hypertension. In 1 study evidence of pulmonary hypertension was noted in 13.4% of patients. Patients with severe COVID-19 were reported to have a higher proportion of pulmonary hypertension as compared to mild COVID-19 disease [22% vs 2%]. Elevated pulmonary artery systolic pressure was significant in predicting mortality. COVID-19 patients with chronic obstructive pulmonary disease, congestive heart failure, myocardial injury, pulmonary embolism, and prior pulmonary hypertension were at a higher risk of worsening pulmonary hypertension. Multiple mechanisms for developing pulmonary hypertension that have been postulated are i) concomitant worsening myocardial injury, ii) cytokine storm, endothelial injury, hypercoagulability attributing to development of venous thromboembolism, iii) and the presence of thrombotic microangiopathy. Among patients with severe COVID-19 disease and pulmonary hypertension, complications including acute respiratory distress syndrome, acute myocardial injury, the requirement of intensive care unit admission, the requirement of mechanical ventilation, and mortality are higher.
- 1 November 2020
- Published by Elsevier in Heart & Lung
- Vol. 49 (6) , 848-852
A review of cardiac manifestations and predictors of outcome in patients with COVID – 19
- 1 November 2020
- Published by Elsevier in Heart & Lung
- Vol. 49 (6) , 848-852
A review of cardiac manifestations and predictors of outcome in patients with COVID – 19
- Open Access
- 27 April 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (2) , 333-336
Cerebrovascular events in COVID-19 patients
Neurological manifestations in patients with COVID–19 are more frequently being reported. Cerebrovascular events have been reported in around 3% of patients. In this review we summarize the published literature on cerebrovascular events in patients with COVID-19 as available on the PubMed database. So far, 3 studies have reported cerebrovascular events. Cerebrovascular events were identified on screening patients with decreased consciousness or in the presence of focal neurological deficits. These events were common in elderly, critically ill patients and in patients with prior cardio-cerebrovascular comorbidities. The diagnosis of cerebrovascular events was confirmed with computed tomography of the brain in most studies reporting neurological events. Multiple pathological mechanisms have been postulated regarding the process of neurological and vascular injury among which cytokine storm is shown to correlate with mortality. Patients with severe illness are found to have a higher cardio- cerebrovascular comorbidity. With an increasing number of cases and future prospective studies, the exact mechanism by which these cerebrovascular events occur and attribute to the poor outcome will be better understood.
- 27 April 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (2) , 333-336
Open AccessCerebrovascular events in COVID-19 patients
Neurological manifestations in patients with COVID–19 are more frequently being reported. Cerebrovascular events have been reported in around 3% of patients. In this review we summarize the published literature on cerebrovascular events in patients with COVID-19 as available on the PubMed database. So far, 3 studies have reported cerebrovascular events. Cerebrovascular events were identified on screening patients with decreased consciousness or in the presence of focal neurological deficits. These events were common in elderly, critically ill patients and in patients with prior cardio-cerebrovascular comorbidities. The diagnosis of cerebrovascular events was confirmed with computed tomography of the brain in most studies reporting neurological events. Multiple pathological mechanisms have been postulated regarding the process of neurological and vascular injury among which cytokine storm is shown to correlate with mortality. Patients with severe illness are found to have a higher cardio- cerebrovascular comorbidity. With an increasing number of cases and future prospective studies, the exact mechanism by which these cerebrovascular events occur and attribute to the poor outcome will be better understood.
- Open Access
- 1 January 2018
- Published by Medknow in Journal of Vector Borne Diseases
- Vol. 55 (4) , 310-314
The relationship between skin rash and outcome in dengue
Background & objectives: Dengue fever (DF) is a common cause of acute febrile illness. Skin involvement is seen in more than half of the patients. This study was aimed to compare the clinical profile and outcome in DF patients with or without skin involvement. Methods: This study included all the patients with DF from the acute febrile illness database of a tertiary care health centre in south India. These patients were further subgrouped into SP and SN (skin involvement positive and negative) based on the presence and absence of skin rash. Differences in clinical presentation, laboratory parameters, disease course, morbidity and outcome among patients with DF with or without skin rash were recorded and analysed statistically. Results: In total 387 patients (>16 yr) with DF were enrolled into the study. Among these 55 patients had evidence of skin rash. Presence of history of overt bleeding (OR = 4.96, p = 0.027) including gum bleeding (OR = 1.17, p = 0.23), epistaxis (OR = 5.52, p = 0.04), and haematuria (OR = 6.41, p = 0.01) were more among patients with SP as compared to SN. The SP patients were found to have lower levels of platelets during the disease course. Patients with SP had a higher percentage of platelet transfusion which was statistically significant. There was no difference in organ dysfunction and mortality among both the groups. Interpretation & conclusion: Cutaneous involvement, though common, is not pathognomonic and can help in dengue diagnosis. Adult patients with skin rash can develop worsening thrombocytopenia requiring platelet transfusion. However, there are limited data to suggest that such patients have a worse outcome and higher mortality.
- 1 January 2018
- Published by Medknow in Journal of Vector Borne Diseases
- Vol. 55 (4) , 310-314
Open AccessThe relationship between skin rash and outcome in dengue
Background & objectives: Dengue fever (DF) is a common cause of acute febrile illness. Skin involvement is seen in more than half of the patients. This study was aimed to compare the clinical profile and outcome in DF patients with or without skin involvement. Methods: This study included all the patients with DF from the acute febrile illness database of a tertiary care health centre in south India. These patients were further subgrouped into SP and SN (skin involvement positive and negative) based on the presence and absence of skin rash. Differences in clinical presentation, laboratory parameters, disease course, morbidity and outcome among patients with DF with or without skin rash were recorded and analysed statistically. Results: In total 387 patients (>16 yr) with DF were enrolled into the study. Among these 55 patients had evidence of skin rash. Presence of history of overt bleeding (OR = 4.96, p = 0.027) including gum bleeding (OR = 1.17, p = 0.23), epistaxis (OR = 5.52, p = 0.04), and haematuria (OR = 6.41, p = 0.01) were more among patients with SP as compared to SN. The SP patients were found to have lower levels of platelets during the disease course. Patients with SP had a higher percentage of platelet transfusion which was statistically significant. There was no difference in organ dysfunction and mortality among both the groups. Interpretation & conclusion: Cutaneous involvement, though common, is not pathognomonic and can help in dengue diagnosis. Adult patients with skin rash can develop worsening thrombocytopenia requiring platelet transfusion. However, there are limited data to suggest that such patients have a worse outcome and higher mortality.
- Open Access
- 9 December 2015
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 93 (6) , 1125-1127
Rare Presentation of Disseminated Histoplasmosis in an Immunocompetent Host
- 9 December 2015
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 93 (6) , 1125-1127
Open AccessRare Presentation of Disseminated Histoplasmosis in an Immunocompetent Host